NeonMind Developing Music Playlist for Psychedelic Therapy
Sessions
Vancouver,
B.C. – April 6, 2021 -- InvestorsHub NewsWire -- NeonMind
Biosciences Inc. (CSE: NEON) (FFE: 6UF)(OTC:NMDBF) ("NeonMind"), is pleased to announce the
commencement of a three phase university study dedicated to
creating an ideal music playlist to accompany therapeutic
psychedelic sessions.
Previous research has established that music for a therapeutic
psychedelic session can significantly impact the
experience.
"The emotional arc of a
musical playlist during a psychedelic session can play an important
role in supporting someone's therapeutic
experience," says Rob Tessarolo, President & CEO of NeonMind.
"Music can act as a pathway that is followed throughout the
patient's journey, taking them to places on an emotional level that
they wouldn't necessarily go without it. Working with Dr. Russo and his
team means we're able to scientifically investigate what have to
date been assumptions about what makes a good playlist."
NeonMind is working
with
Dr. Frank
Russo, a professor of Psychology at Ryerson University, who
conducts research on the biological,
cognitive, and social-emotional bases of music and speech at the
Science of Music Auditory Research and Technology (SMART)
Lab. He is also an affiliate scientist at the Toronto
Rehabilitation Institute, a core member of the
McMaster
Institute for Music and the Mind, and an adjunct professor at the
University of Toronto's Music and Health Collaboratory.
NeonMind will conduct the
research in three
phases:
- an online playlist candidate
validation study, surveying 50 people with relation to the
self-transcendent emotions experienced when listening to snippets
of longer musical tracks;
- an in-person playlist
validation study at Ryerson's SMART Lab; and
- a comprehensive in-person
physiological validation study measuring biological
markers to
further substantiate the potential for self-transcendent emotions
that the playlist in question generates.
"This is an exciting frontier
to be a part of that dovetails nicely with several aspects of
research that I've been conducting into the
psychology
of music throughout my career," says Dr. Russo. "Music without a
psychedelic has the potential to generate self-transcendent
emotions such as compassion and awe, which may be transformative;
on the basis of past research on music and psychedelics, it
seems that
the music a person listens to during a therapeutic trip is a major
determinant of the overall experience. The playlist we are working
towards takes various theoretical considerations into account, and
the series of studies we've designed will enable us to iteratively assess
and refine its efficacy."
Each phase will help the team
assess and fine-tune the playlist which will then be used in
NeonMind's clinical trials and for the enhancement of
psychedelic-assisted psychotherapy services.
About NeonMind
Biosciences Inc.
NeonMind is
engaged in research and development of products to optimize human
health and performance. NeonMind has two divisions, a
pharmaceutical division engaged in drug development of psychedelic
compounds, and a consumer products division with a focus on
mushroom infused products. NeonMind's consumer division currently
sells medicinal mushroom infused coffee products in Canada through
NeonMind's direct to consumer e-commerce platform. It also plans to
launch medicinal dietary supplements in the U.S.
this spring[1][2][3].
In its
pharmaceutical division, NeonMind has two distinct psilocybin drug
development programs targeting obesity. NeonMind's first drug
candidate aims to use synthetic psilocybin to enhance a patient's
ability to adopt behaviours that cause
weight loss and maintain that loss through
psychedelic-assisted
cognitive therapy. The second drug candidate offers low dose
synthetic psilocybin as a treatment to suppress
appetite.
NeonMind's first
drug candidate employs psilocybin as an agonist to the
serotonin receptor 5- HT2A, which is involved in the hallucinogenic
effect of psychedelics, and the second drug candidate employs
low-dose psilocybin as an agonist to the 5-HT2C receptor, which
controls appetite.
For more
information on NeonMind, go
to
www.NeonMindBiosciences.com or buy NeonMind mushroom
infused coffee at
www.NeonMind.com.
Rob
Tessarolo, President & Chief Executive Officer, NeonMind
Biosciences Inc.
rob@neonmind.com
Tel: 416-750-3101
Investor
Relations:
Edge
Communications
invest@neonmind.com
Tel:
1-866-318-6874
Renmark
Financial Communications Inc.
Melanie
Barbeau
mbarbeau@renmarkfinancial.com
Tel: 416-644-2020 or
212-812-7680
Media
Inquiries:
Exvera
Communications Inc.
brittany@exvera.com
The
Canadian Securities Exchange has not reviewed, approved or
disapproved the contents of this news release.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained in this press release constitute
forward-looking information. These statements relate to future
events or NeonMind's future performance. The use of any of the
words "could", "expect", "believe", "will",
"projected","estimated"
and similar expressions and statements relating to matters that are
not historical facts are intended to identify forward-looking
information and are based on NeonMind's current belief or
assumptions as to the outcome and timing of such future
events.
Actual future results may differ materially. In particular,
NeonMind's drug development plans, its ability to retain key
personnel, and its expectation as to the development of its
intellectual property and other steps in its preclinical and
clinical drug
development constitute forward-looking information. Actual results
and developments may differ materially from those contemplated by
forward-looking information. Readers are cautioned not to place
undue reliance on forward-looking information. The
statements
made in this press release are made as of the date hereof. NeonMind
disclaims any intention or obligation to publicly update or revise
any forward-looking information, whether as a result of new
information, future events or otherwise, except as may
be
expressly required by applicable securities laws.